Open Access

Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2

  • Authors:
    • Johanna Dalmo
    • Nils Rudqvist
    • Johan Spetz
    • Peter Laverman
    • Ola Nilsson
    • Håkan Ahlman
    • Eva Forssell-Aronsson
  • View Affiliations

  • Published online on: October 6, 2011     https://doi.org/10.3892/or.2011.1494
  • Pages: 174-181
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To be able to evaluate new radiopharmaceuticals and optimize diagnostic and therapeutic procedures, relevant animal models are required. The aim of this study was to evaluate the medullary thyroid carcinoma GOT2 animal model by analyzing the biodistribution of 177Lu-octreotate and 111In-minigastrin (MG0). BALB/c nude mice, subcutaneously transplanted with GOT2, were intravenously injected with either 177Lu-octreotate or 111In-MG0, with or without excess of unlabeled human minigastrin simultaneously with 111In-MG0. Animals were sacrificed 1-7 days after injection in the 177Lu-octreotate study and 1 h after injection of 111In-MG0. The activity concentrations in organs and tissues were determined and mean absorbed doses from 177Lu were calculated. There was a specific tumor uptake of either 177Lu-octreotate or 111In-MG0. 177Lu-octreotate samples showed high activity concentrations in tissues expressing somatostatin receptors (SSTR). For both radiopharmaceuticals the highest activity concentrations were found in the kidneys. Compared to results from similar studies in mice with another MTC cell line (TT) the biodistribution was favorable (higher tumor uptake) for the GOT2 model, while compared to other animal models expressing SSTR, the tumor uptake of 177Lu-octreotate was modest. In conclusion, the GOT2 animal model is a valuable model for evaluation and optimization of diagnostic and therapeutic procedures using radiolabeled somatostatin, CCK2 and gastrin analogues prior to clinical studies.

Related Articles

Journal Cover

January 2012
Volume 27 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Dalmo J, Rudqvist N, Spetz J, Laverman P, Nilsson O, Ahlman H and Forssell-Aronsson E: Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. Oncol Rep 27: 174-181, 2012
APA
Dalmo, J., Rudqvist, N., Spetz, J., Laverman, P., Nilsson, O., Ahlman, H., & Forssell-Aronsson, E. (2012). Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. Oncology Reports, 27, 174-181. https://doi.org/10.3892/or.2011.1494
MLA
Dalmo, J., Rudqvist, N., Spetz, J., Laverman, P., Nilsson, O., Ahlman, H., Forssell-Aronsson, E."Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2". Oncology Reports 27.1 (2012): 174-181.
Chicago
Dalmo, J., Rudqvist, N., Spetz, J., Laverman, P., Nilsson, O., Ahlman, H., Forssell-Aronsson, E."Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2". Oncology Reports 27, no. 1 (2012): 174-181. https://doi.org/10.3892/or.2011.1494